CANCIDAS
Total Payments
$207,392
Transactions
11
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $30,396 | 2 | 0 |
| 2020 | $49,849 | 2 | 0 |
| 2019 | $30,000 | 1 | 0 |
| 2017 | $97,147 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $207,392 | 11 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label Phase III Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic Hematopoietic Cell Transplantation | Merck Sharp & Dohme Corporation | $80,829 | 0 |
| A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections In Children Undergoing Chemotherapy For Acute Myelogenous Leukemia AML | Merck Sharp & Dohme Corporation | $72,500 | 0 |
| Retrospective study of the utilization of posaconazole and caspofungin in hospitalized children in the United States. | Merck Sharp & Dohme Corporation | $34,758 | 0 |
| Beta-D-glucan Assay for Diagnosing Invasive Fungal Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients | Merck Sharp & Dohme Corporation | $19,057 | 0 |
| A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants Less Than 3 Months of Age | Merck Sharp & Dohme Corporation | $248.00 | 0 |
Top Doctors Receiving Payments for CANCIDAS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $207,392 | 11 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $207,392
Product Information
- Type Drug
- Total Payments $207,392
- Total Doctors 0
- Transactions 11
About CANCIDAS
CANCIDAS is a drug associated with $207,392 in payments to 0 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2021. In 2021, $30,396 was paid across 2 transactions to 0 doctors.
The most common payment nature for CANCIDAS is "Unspecified" ($207,392, 100.0% of total).
CANCIDAS is associated with 5 research studies, including "An Open-Label Phase III Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections Undergoing Allogeneic Hematopoietic Cell Transplantation" ($80,829).